Paper Details

  1. Home
  2. Paper Details

Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.

Author: CorselloAndrea, CorselloSalvatore Maria, LocantorePietro, NovizioRoberto, ParagliolaRosa Maria, PontecorviAlfredo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Targeted therapies have become increasingly important in treating RET-mutated thyroid and other solid cancers. While Multi-Kinase Inhibitors (MKIs) have been approved by the FDA, their limited efficacy and side effects pose challenges. Pralsetinib, an oral, highly selective RET inhibitor, has been developed and clinically validated for its higher potency and lower toxicity.
Paper Details　
Original Abstract of the Article :
The use of targeted drug therapies has substantially increased in the treatment of RET-mutated thyroid and other solid cancers over the last decade. Multi-Kinase Inhibitors (MKI) have been approved by FDA, but limited efficacies and side effects make them uneasy to tolerate. Pralsetinib is an oral h...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17460441.2022.1995351

データ提供：米国国立医学図書館（NLM）

Pralsetinib: A New Oasis in the Desert of RET-Mutated Thyroid Cancer

The search for effective treatments for RET-mutated thyroid cancer has been a long and challenging journey, akin to traversing a vast and unforgiving desert. This study, like a well-mapped trail, introduces pralsetinib, a highly selective RET inhibitor, as a promising new treatment option.

Pralsetinib: A Potential Beacon of Hope in the Desert of Thyroid Cancer

Pralsetinib has shown high potency and low toxicity, offering a significant improvement over previous multi-kinase inhibitors (MKIs), which often have limited efficacy and troublesome side effects. This new drug, like a refreshing spring in the desert, has the potential to transform the treatment landscape for RET-mutated thyroid cancer.

Navigating the Desert of Thyroid Cancer Treatment

This study offers a beacon of hope for patients with RET-mutated thyroid cancer. Pralsetinib's impressive profile suggests a potential for more effective and tolerable treatment, offering a glimmer of hope in the desert of this challenging disease. However, as with any oasis in the desert, continued research is crucial to fully understand the long-term effects and optimize its use in clinical practice.

Dr.Camel's Conclusion

This study introduces pralsetinib, a potential game-changer in the treatment of RET-mutated thyroid cancer. This promising new drug, like a refreshing spring in the desert, offers hope for more effective and tolerable treatment. However, further research is needed to fully explore its potential and ensure its safe and effective application in the clinical setting.

Date :
  1. Date Completed 2022-03-03
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34702125

DOI: Digital Object Identifier

10.1080/17460441.2022.1995351

Related Literature

Article Analysis
・Side Effects of pralsetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.